Fineos’ (ASX.FCL) third-quarter fiscal 2026 update revealed a 59% increase in cash balance from the same time last year. Customer receipts and free cash flow increased 8% and 230% on a yearly basis, respectively. Full-year revenue guidance remains EUR 147 million-EUR 152 million, an 8% rise at the midpoint.

Why it matters: The update reaffirms our earnings growth and margin expansion thesis, driven by existing customers buying more product, fixed costs scaling, and longer-term new customer wins. Margin expansion is more obvious than new volume growth, which could be holding the stock back.

  • Yearly operating cash outflows fell to 72% of customer receipts from 77% at the same time last year, and free cash flow rose to 36% of operating cash flow from 14%. Both point to wider operating margins as costs grow more slowly than the cash customers pay.
  • No new sales were finalized in the quarter, but wins over the past two quarters already exceed or match the prior two fiscal years, and clients like OneAmerica recently expanded their use of Fineos. Sales are lumpy, and we don’t see any specific cause for concern.

The bottom line: We retain our fair value estimate of $3.30 for narrow-moat Fineos. Shares are considerably undervalued. Earnings look more durable than current prices imply, as customers who adopt Fineos keep buying more and each extra module raises the cost of leaving.

  • Artificial intelligence is unlikely to make Fineos irrelevant. US regulators hold insurers responsible for AI use, including vendors’ systems, so we think they will favor certified, audited platforms like Fineos. Scattered data also makes AI automation difficult and is likely to push insurers toward a single platform.
  • We think insurers that believed AI could replace Fineos would not be committing to it more and more. OneAmerica signed a 10-year deal to run its US employee benefits business on Fineos’ most comprehensive product, and Guardian Life will start moving older systems onto the new platform.

Shares of Fineos remain materially undervalued

Fineos is a core software vendor to the global life, accident, and health, or LA&H, insurance industry. Customers are primarily large multinationals and midmarket insurers. The firm generates revenue mainly from subscriptions and product implementation services. About 80% of revenue is generated from the US, the rest from the Asia-Pacific and Europe.

Fineos helps insurers streamline workflow, save costs, and win new business. Benefits of Fineos’ products to insurers include automating/unifying work processes, centralizing data, reducing the time to market for new products, and enabling greater user interface, assisting business wins and client retention. Fineos is currently migrating customers to a cloud-based offering (from on-premises products). This makes it easier to roll out new features and support at lower marginal costs, while also providing more recurring subscription revenue.

The firm executes a classic land and expand strategy. Building on its leadership in claims and absence products, Fineos aims to cross-sell its broader product set including payments, billing, data and more. It intends to expand the use of the Fineos platform across multiple jurisdictions with existing multinational clients. Higher customer expectations, cost pressures, regulatory requirements, or increasing competition are prompting insurers to switch from clunky internal systems to external software like that from Fineos.

There is ample room for Fineos to deploy new modules to existing customers and grow penetration over time. This further increases switching costs. To date, around half of insurers globally still use in-house legacy systems with limited functionality and high operating costs. Fineos has built multiple reference accounts from doing business with large insurers, which help with additional business wins.

Risks include competition from larger software firms or smaller, AI-native competitors, and customer concentration, which may limit price hikes. These may be offset by Fineos’ high switching costs and the risk aversion of insurer clients in changing core systems. Fineos’ product switching costs are contingent on the group continuing to invest to add value to customers.

Bulls Say

  • Fineos has low penetration in a sleepy industry that’s ripe for disruption. Operating metrics are solid and trending positively.
  • Switching costs are high. A competitor who creates a better product only wins half the race. The other half is to build credible reference accounts and convince insurers to switch, which can be a lengthy ordeal.
  • We believe Fineos will remain the leader in its niche space, as it continues to reinvest in its products or pursue acquisitions, bolstering its capabilities, increasing the switching costs of its product suite, and expanding the modules on offer.

Bears Say

  • As a vendor to large insurers, Fineos could lose its relevance if it does not innovate and improve. Operating margins can be constrained by high investment needs.
  • Fineos’ pricing power has yet to be fully tested. Customer concentration is an immediate inhibitor. Longer term, there may be more rapid technological advancements that make switching to another platform easier.
  • Tying subscription revenue to gross written premiums—rather than a set fee—exposes Fineos to the ebb and flow of the insurance cycle. Revenue might be recurring, but the quantum may not always be consistent.

Subscribe to get Morningstar insights in your inbox